It is implicated in the sensitivity of colorectal cancer cell lines to cetuximab (Du et al., 2016), and in lung cancer cells, it potentially leads to cisplatin resistance via ERK-mediated Bcl-2 transcriptional activation (Chawhan & Dsouza, 2024). This evidence concerns the gene BCL2 and lung carcinoma.